Fig. 2: The efficacy of EMB-02 was demonstrated using a waterfall plot, which illustrates the percentage change from baseline in the sum of diameters of target lesions. | British Journal of Cancer

Fig. 2: The efficacy of EMB-02 was demonstrated using a waterfall plot, which illustrates the percentage change from baseline in the sum of diameters of target lesions.

From: First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors

Fig. 2

The plot included 37 patients. Five patients were excluded due to the absence of measurable target lesions at baseline, and another five were excluded due to the lack of post-baseline radiological target lesion assessments. One ESCC patient with a BOR of CR was not represented in the plot due to the absence of a target lesion at baseline. Subjects who received prior treatment with an anti-PD-1/L1 inhibitor are indicated with an asterisk (*). For ten CRC patients, all of them were MSS. ACCPG Adenoid Cystic Carcinoma of the parotid gland, ASCC Anal squamous cell carcinoma (ASCC), CRC colorectal cancer, EAC esophageal adenocarcinoma, EC endometrial carcinoma, ESCC esophageal squamous cell carcinoma (ESCC), GC gastric cancer, HNSCC head and neck squamous cell carcinoma, LMS leiomyosarcoma, C-MEL cutaneous melanoma, A-MEL acral melanoma, M-MEL mucosal melanoma, NSCLC non-small cell lung cancer, RCC renal cell carcinoma, SCC UNK metastatic SCC of unknown primary, TNBC triple negative breast cancer, ThyCa Thyroid Carcinoma.

Back to article page